November 12, 2015
Akers Biosciences in managerial changes
Akers Biosciences has appointed Raza Bokhari M.D. as a Non-executive Director of the company.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
November 12, 2015
Silence Therapeutics welcomes new board member
Silence Therapeutics plc, a London-headquartered drug development company, dealing with the delivery of novel RNA interference (RNAi) therapeutics for the treatment…
November 12, 2015
Study shows IONA test can predict the presence of Down’s, Edward’s, and Patau’s syndrome
Study demonstrates the IONA test can accurately predict the presence of the trisomies 21, 18, and 13. Being user-friendly, cost effective and CE-marked will overcome some of the limitations of existing commercial technologies to facilitate implementation in local laboratories.
November 11, 2015
Horizon Pharma about Express Scripts’ business practices
Horizon Pharma about Express Scripts’ business practices: “Express Scripts… also operates its own mail-order pharmacy and thus is a direct competitor of small, independent specialty pharmacies”
November 11, 2015
Horizon Pharma and ALR will together study RAYOS
Horizon Pharma on Wednesday announced a collaboration with the Alliance for Lupus Research (ALR) to study RAYOS (prednisone) delayed-release tablets in systemic lupus erythematosus (SLE).
November 11, 2015
Anavex confirms positive efficacy Phase2 Alzheimer’s trial for its Anavex 2-73 datahad
Anavex has confirmed the information about positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.
November 11, 2015
4D pharma gets OK for clinical trial of Thetanix
4D pharma has obtained regulatory and ethical approval for a phase 1 clinical trial in respect of Thetanix.
November 11, 2015
Biofrontera’s business not affected by ongoing approval processes
Biofrontera has announced that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the Company.
November 11, 2015
Plavix does not affect overall risk of death in patients with heart disease.
Long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease.
November 11, 2015
Diplomat to dispense melanoma drug “Cotellic” in combination with “Zelboraf”
Diplomat Pharmacy, NYSE-listed pharmaceutical company, will dispense Cotellic in combination with the BRAF inhibitor Zelboraf to treat patients with advanced melanoma that cannot be removed by surgery, or that has spread from the primary site.